Journal article icon

Journal article

Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib

Abstract:

Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical response in 40% of treated patients with relapsed/refractory AML by promoting leukemic cell differentiation. Here, we studied the clonal basis of response and acquired resistance to enasidenib treat...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1038/s41591-018-0115-6

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences
Department:
RDM
Oxford college:
St Annes College
Role:
Author
ORCID:
0000-0003-3931-0914
More by this author
Institution:
University of Oxford
Division:
Medical Sciences
Department:
RDM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences
Department:
RDM
Role:
Author
Expand authors...
Publisher:
Springer Nature Publisher's website
Journal:
Nature Medicine Journal website
Volume:
24
Issue:
1
Pages:
1167–1177
Publication date:
2018-07-16
Acceptance date:
2018-05-16
DOI:
EISSN:
1546-170X
ISSN:
1078-8956
Pubs id:
pubs:864248
URN:
uri:8156c058-38e7-4287-9972-a993fac4fc8e
UUID:
uuid:8156c058-38e7-4287-9972-a993fac4fc8e
Local pid:
pubs:864248

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP